222.30 USD
-1.55
0.69%
At close Apr 1, 4:00 PM EDT
After hours
222.30
+0.00
0.00%
1 day
-0.69%
5 days
0.37%
1 month
-4.63%
3 months
-2.70%
6 months
-6.89%
Year to date
-2.70%
1 year
17.42%
5 years
56.23%
10 years
211.39%
 

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 10,140

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

116% more first-time investments, than exits

New positions opened: 145 | Existing positions closed: 67

28% more repeat investments, than reductions

Existing positions increased: 329 | Existing positions reduced: 257

8% more funds holding

Funds holding: 785 [Q3] → 848 (+63) [Q4]

2.23% more ownership

Funds ownership: 59.17% [Q3] → 61.4% (+2.23%) [Q4]

3% less capital invested

Capital invested by funds: $21.2B [Q3] → $20.6B (-$577M) [Q4]

30% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 7 (-3) [Q4]

79% less call options, than puts

Call options by funds: $86.1M | Put options by funds: $416M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$240
8%
upside
Avg. target
$267
20%
upside
High target
$286
29%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
Stifel
Jonathan Block
11% 1-year accuracy
2 / 19 met price target
8%upside
$240
Hold
Maintained
5 Mar 2025
JP Morgan
David Low
0% 1-year accuracy
0 / 1 met price target
29%upside
$286
Overweight
Maintained
31 Jan 2025
Keybanc
Brett Fishbin
24% 1-year accuracy
4 / 17 met price target
26%upside
$280
Overweight
Maintained
31 Jan 2025
Piper Sandler
Adam Maeder
57% 1-year accuracy
8 / 14 met price target
17%upside
$260
Neutral
Maintained
31 Jan 2025

Financial journalist opinion

Based on 9 articles about RMD published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine , demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that CPAP therapy not only alleviates OSA symptoms but can also prolong life.
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
Positive
Zacks Investment Research
2 weeks ago
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Positive
Zacks Investment Research
2 weeks ago
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space.
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
Positive
Zacks Investment Research
2 weeks ago
RMD Stock Likely to Benefit From the New Brand Evolution Strategy
In another major brand update, Resmed is likely to unify all the brands under one identity.
RMD Stock Likely to Benefit From the New Brand Evolution Strategy
Neutral
GlobeNewsWire
3 weeks ago
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions.
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
Neutral
Zacks Investment Research
3 weeks ago
Is it Worth Adding ResMed Stock to Your Portfolio Now?
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Is it Worth Adding ResMed Stock to Your Portfolio Now?
Positive
Zacks Investment Research
3 weeks ago
5 Best Dividend Growth Stocks to Buy Amid Trade War Fears
Investors searching for safe and consistent income amid global trade war fears. Dividend growth stocks like TSM, TPR, ABM, VRT and RMD are solid choices.
5 Best Dividend Growth Stocks to Buy Amid Trade War Fears
Positive
Zacks Investment Research
3 weeks ago
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
Positive
Seeking Alpha
4 weeks ago
My Top 15 High-Growth Dividend Stocks For March 2025
The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate.
My Top 15 High-Growth Dividend Stocks For March 2025
Positive
Zacks Investment Research
1 month ago
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why ResMed (RMD) is a Strong Growth Stock
Charts implemented using Lightweight Charts™